Australia's Clinuvel Pharmaceuticals falls as US shutdown delays SEC filings

Clinuvel Pharmaceuticals

03/11/2025 02:30

** Shares of Clinuvel Pharmaceuticals CUV.AX down as much as 2.5% to A$11.21

** The specialty pharma co anticipates that the U.S. Federal government shutdown will impact timelines for review and approval of registration statements to be filed with the U.S. Securities and Exchange Commission (SEC)

** "Feedback from the U.S. administration, however, indicates a longer-than-anticipated turnaround of filing reviews," says co

** Stock down 5.7% YTD, including the day's moves

 (Reporting by Shivangi Lahiri in Bengaluru)

 ((shivangi.lahiri@thomsonreuters.com))